Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $33.9 million.

  • Nurix Therapeutics' Share-based Compensation rose 11.63% to $9.8 million in Q3 2025 from the same period last year, while for Aug 2025 it was $37.4 million, marking a year-over-year increase of 11.79%. This contributed to the annual value of $33.9 million for FY2024, which is 0.76% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Share-based Compensation of $33.9 million as of FY2024, which was up 0.76% from $33.7 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Share-based Compensation ranged from a high of $33.9 million in FY2024 and a low of $4.3 million during FY2020.
  • Over the past 3 years, Nurix Therapeutics' median Share-based Compensation value was $33.7 million (recorded in 2023), while the average stood at $31.9 million.
  • Data for Nurix Therapeutics' Share-based Compensation shows a peak YoY spiked of 743.33% (in 2020) over the last 5 years.
  • Over the past 5 years, Nurix Therapeutics' Share-based Compensation (Yearly) stood at $4.3 million in 2020, then soared by 267.36% to $15.8 million in 2021, then surged by 78.04% to $28.1 million in 2022, then climbed by 19.70% to $33.7 million in 2023, then rose by 0.76% to $33.9 million in 2024.